TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Approaches and emerging therapies for TP53 AML

By Claire Baker

Share:

Featured:

Naval DaverNaval Daver

Jul 2, 2020


During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to a member of our steering committee, Naval Daver, The University of Texas MD Anderson Cancer Center, Houston, US, about novel approaches and emerging therapies for TP53 AML.

Approaches and emerging therapies for TP53 AML

Identification of disease-driving genetic aberrations has allowed for major advancements in the AML setting. TP53 mutations are observed in around 15% of patients with AML, with distinct patterns between patient subsets. Despite the development of targeted therapies, such as FLT3 and IDH1/2 inhibitors, treatments targeting TP53 mutations are yet to be established.

TP53-mutant AML is an area of unmet need, demonstrating high interpatient heterogeneity. Here, Naval Daver describes the efforts being made to establish TP53 as a therapeutic target, with the aim to further improve patient outcomes.


More about...